医疗服务行业周报2025.12.29-2026.1.2：英矽智能港股挂牌，AI制药潜力大-20260103

Investment Rating - The report maintains a "Buy" rating for the medical services industry [5][66]. Core Insights - The medical and biological sector experienced a decline of 2.06% this week, ranking 28th among 31 primary industries [1][11]. - The AI pharmaceutical company Insilico Medicine was listed on the Hong Kong Stock Exchange, raising HKD 2.277 billion, marking it as the highest fundraising biotech IPO in 2025 [4][63]. - AI technology is significantly reducing the time and costs associated with drug discovery and clinical trials, with potential savings of approximately USD 26 billion annually in compound screening and clinical trial costs [5][65]. Summary by Sections Industry Performance - The medical services sector's PE (ttm) is 31.28X, with a PB (lf) of 3.17X, showing a decrease of 0.52X in PE and 0.05X in PB from the previous week [3][30]. - The medical services II sub-industry index closed at 6363.18 points, down 1.40% [22][23]. Company Performance - Top-performing companies in the medical services sector include: - Purui Eye Hospital (+5.3%) - Sanbo Brain Science (+4.7%) - Puris (+3.0%) - Tigermed (+2.9%) - Baicheng Pharmaceutical (+2.2%) - Underperforming companies include: - Bid Pharmaceutical (-6.6%) - Sunshine Nuohua (-6.1%) - Zhaoyan New Drug (-5.2%) - International Medicine (-4.0%) - Kanglong Chemical (-3.5%) [2][28]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing services, with companies like WuXi AppTec, Haoyuan Pharmaceutical, and WuXi Biologics being highlighted [9][66]. - It also recommends looking at third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry, with companies like Aier Eye Hospital and Dean Diagnostics [9][66].